| Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 |
Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with high price targets, and robust patent protection highlight growing confidence and upside potential. Data readout for the NEAT Phase 3 trial is scheduled for early 2026, with all patients joining the open-label extension, and cash runway aligns with expected topline results. |
seekingalpha.com |
2025-05-15 13:50:15 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2025. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “In light of current cash runway and with the goal of maxim. |
businesswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Present at Citizens Life Sciences Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time. A live webcast of the presentation. |
businesswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025. A replay of the presentation will be accessible on the Events page under the Ne. |
businesswire.com |
2025-04-03 20:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the fiscal year ended December 31, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “Our Phase 3 pivotal NEAT clinical trial has exceeded 50%. |
businesswire.com |
2025-03-24 18:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced that it will host an investor webinar today, Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time, featuring key opinion leader (KOL) Dr. Mary Kay Koenig from UTHealth Houston with a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia. |
businesswire.com |
2025-02-07 10:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 12, 2025 beginning at 2:00 p.m. Easter. |
businesswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/083,771 entitled Process for the Preparation of Erythrocytes Loaded With One or More Substances of Pharmaceutical Interest and So Obtained Erythrocytes. |
businesswire.com |
2025-02-04 18:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it will host an investor webinar focused on addressing the high unmet need in the company's lead rare pediatric neurodegenerative disease indication, Ataxia-Telangiectasia (A-T). The virtual webinar event will take place on Friday, February 7, 2025, beginning. |
businesswire.com |
2025-01-28 10:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the online publication of safety data from patients with Ataxia-Telangiectasia (A-T) treated with EryDex for a minimum of 24 months in Frontiers in Neurology. “A-T is a rare pediatric disease with unmet medical need and no approved therapeutic treatment. This post-hoc a. |
businesswire.com |
2025-01-27 10:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trus. |
businesswire.com |
2025-01-23 18:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the third quarter ended September 30, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “We are pleased to report accelerating enrollment of ou. |
businesswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial. The objective of the data analysis was to. |
businesswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Participate at Upcoming Investor Conferences |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences: 2024 Maxim Healthcare Virtual Summit – Quince's Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3. |
businesswire.com |
2024-10-14 20:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex |
Quince's transformation is complete with the acquisition of EryDel in October 2023. The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of EryDel's earlier trial. Chances for success are high, with approval and multi-billion dollar potential around the corner after topline data next year. |
seekingalpha.com |
2024-08-20 01:16:41 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the online publication of data in The Lancet Neurology from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial evaluating the safety and efficacy of its lead asset, EryDex (dexamethasone sodium phosph. |
businesswire.com |
2024-08-15 11:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the first patient has been dosed in the company's Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T) clinical trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia (A-T). |
businesswire.com |
2024-06-25 11:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia (A-T). EryDex is comprised of dexamethasone sodium phosphate (DS. |
businesswire.com |
2024-06-03 11:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “Our primary corporate. |
businesswire.com |
2024-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 beginning at 1:30 p.m. Eastern Time. A live webcast of the pres. |
businesswire.com |
2024-05-06 20:05:00 |
Czytaj oryginał (ang.) |
| Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma |
Two microcap biotech stocks to consider for the science-challenged among us. |
zacks.com |
2024-03-07 19:51:04 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Launches Scientific Advisory Board |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the launch of a Scientific Advisory Board (SAB) comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. “We are pleased to announce the formation of our Scientific Advisor. |
businesswire.com |
2024-02-22 09:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. “We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's calib. |
businesswire.com |
2024-02-15 09:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 14, 2024 beginning at 10:40 a. |
businesswire.com |
2024-02-07 18:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Participate at Investor Events in January 2024 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will participate at two investor events taking place in San Francisco, California in January 2024: 7th Annual Neuroscience Innovation Forum (NIF) – Sun. |
businesswire.com |
2024-01-04 18:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Completes Acquisition of EryDel S.p.A. |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company. Quince's newly acquired Phase 3 lead asset, EryDex, targets a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). Current. |
businesswire.com |
2023-10-23 11:00:00 |
Czytaj oryginał (ang.) |
| U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that the U.S. Food and Drug Administration (FDA or the “Agency”) has lifted the partial clinical hold on EryDel S.p.A's Investigational New Drug (IND) application for its lead Phase 3 asset, EryDex. Pending the closing of Quince's acquisition of EryDel, Quince. |
businesswire.com |
2023-09-28 20:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics Appoints Dr. Charles S. Ryan as President |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S. |
businesswire.com |
2023-09-06 11:00:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, announced that Dirk Thye, M.D., the company's Chief Executive Officer, will present at the Sidoti Virtual Investor Conference on Thursday, August 17, 2023, at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time). A live webcast of the investor presentation will be accessible on th. |
businesswire.com |
2023-08-10 20:05:00 |
Czytaj oryginał (ang.) |
| Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that the company has entered into an agreement to acquire EryDel SpA, a privately-held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream milestone cash payments. EryDel has developed an autologous intracellular drug enc. |
businesswire.com |
2023-07-24 11:00:00 |
Czytaj oryginał (ang.) |
| Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc. |
Offers $1.80 per share in cash plus CVR to receive 85% of the future net proceeds Quince receives as part of the Lighthouse Pharmaceuticals transaction Stock trades below its net cash and investments balance of approximately $2.30 per share Willing to increase cash component of the offer if company can demonstrate that its net cash at closing would be higher than we currently estimate Offer's cash component alone represents 115% premium to company's stock price before our original buyout offer in March NEW YORK, NY / ACCESSWIRE / July 13, 2023 / Earlier today Echo Lake Capital issued a letter to the Board of Directors of Quince Therapeutics, Inc. (NASDAQ:QNCX). The letter described a revised proposal to acquire all the company's common stock for $1.80 per share in cash plus a CVR to receive 85% of the future net proceeds received from the Lighthouse Pharmaceutical transaction announced on January 27, 2023. |
accesswire.com |
2023-07-13 12:00:00 |
Czytaj oryginał (ang.) |